Core Viewpoint - Polyrizon Ltd. has initiated preclinical studies for intranasal Benzodiazepines (BZDs) aimed at improving emergency treatment options for acute repetitive seizures and status epilepticus using its proprietary drug delivery platform [1][5][8]. Company Summary - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels and drug delivery systems, including its Trap and Target™ (T&T) platform for administering BZDs [1][8]. - The company is collaborating with Professor Fabio Sonvico from the University of Parma, an expert in intranasal drug delivery solutions, to conduct these preclinical studies [4]. Industry Summary - The global acute repetitive seizures market was valued at approximately USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030 [2]. - The global epilepsy treatment devices market was valued at around USD 526.8 million in 2023 and is expected to reach approximately USD 787.3 million by 2033, growing at a CAGR of about 4.1% from 2024 to 2033 [3].
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment